# Biology of Blood and Marrow Transplantation

**Official Publication of the American Society for Blood and Marrow Transplantation**

## Author Information Pack

### Table of Contents

- **Description** p.1
- **Audience** p.1
- **Impact Factor** p.1
- **Abstracting and Indexing** p.1
- **Editorial Board** p.2
- **Guide for Authors** p.4

### Description

*Biology of Blood and Marrow Transplantation* publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Blood and Marrow Transplantation.

The journal focuses on current technology and knowledge in the interdisciplinary field of **hematopoietic stem cell transplantation**.

### Benefits to Authors

- **Benefits to authors**: We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our [author services](https://www.elsevier.com/author-resources).

- **Please see our Guide for Authors** for information on article submission. If you require any further information or help, please visit our [Support Center](https://www.elsevier.com/support-center).

### Audience

Hematologists, Oncologists, Pediatric Hematologists/Oncologists, Immunologists, Researchers in Gene Therapy

### Impact Factor

2017: 4.484 © Clarivate Analytics Journal Citation Reports 2018

### Abstracting and Indexing

- MEDLINE®
- EMBASE
- Excerpta Medica
- Chemical Abstracts
- Current Contents/Clinical Medicine
- Science Citation Index
- SciSearch
EDITORIAL BOARD

Editor-in-Chief
Robert Korngold, Hackensack University Medical Center, Hackensack, New Jersey, USA

Associate Editors
J. H. Antin, Harvard Medical School, Boston, Massachusetts, USA
A. Bacigalupo, Ospedale San Martino, Genova, Italy
J. Brown, Stanford University, Stanford, California, USA
N. Chao, Duke University, Durham, North Carolina, USA
E. Copelan, Cleveland Clinic Foundation, Cleveland, Ohio, USA
M. De Lima, University Hospitals Case Medical Center, Cleveland, Ohio, USA
D. Fowler, National Institutes of Health (NIH), Bethesda, Maryland, USA
H. E. Heslop, Baylor College of Medicine, Houston, Texas, USA
R. Levy, University of Miami, Miller School of Medicine, Miami, Florida, USA
D. P. Lu, Shanghai Institute of Hematology, Shanghai, China
P. L. McCarthy, Roswell Park Cancer Institute, Buffalo, New York, USA
Y. Morishima, Aichi Cancer Center Research Institute, Nagoya, Japan
P. Reddy, University of Michigan Medical School, Ann Arbor, Michigan, USA
B. Revani, Vanderbilt University Medical Center, Nashville, Tennessee, USA
E. J. Shpall, University of Texas, Houston, Texas, USA
G. Socié, Hôpital Saint-Louis, Paris, France
R. J. Soiffer, Harvard Medical School, Boston, Massachusetts, USA
R. Storb, University of Washington, Seattle, Washington, USA
M. Verneris, University of Colorado Denver, Denver, Colorado, USA
J. R. Wingard, University of Florida, Gainesville, Florida, USA
J. H. Young, University of Minnesota Medical School, Minneapolis, Minnesota, USA

Editorial Board
Amin Alousi, MD Anderson Cancer Center, Houston, Texas, USA
Claudio Anasetti, H. Lee Moffitt Cancer Center, Tampa, Florida, USA
Smita Bhatia, City of Hope National Medical Center, Duarte, California, USA
Didier Blaise, Centre de Recherche en Cancérologie de Marseille
Catherine Bollard, Children’s National Medical Center, Washington, District of Columbia, USA
Christopher Bredeson, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Linda Burns, National Marrow Donor Program, Minneapolis, Minnesota, USA
Matthew Carabasi, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Richard E. Champlin, University of Texas, Houston, Texas, USA
Benny Chen, Duke University Medical Center, Durham, North Carolina, USA
George Chen, Roswell Park Cancer Institute, Buffalo, New York, USA
Yi-Bin Chen, Massachusetts General Hospital, Boston, Massachusetts, USA
Sung Choi, University of Michigan Health System, Ann Arbor, Michigan, USA
Kenneth Cooke, Johns Hopkins University, Baltimore, Maryland, USA
Daniel Couriel, University of Utah School of Medicine, Salt Lake City, Utah, USA
Corey Cutler, Harvard Medical School, Boston, Massachusetts, USA
Joachim Deeg, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Steven Devine, Ohio State University Medical Center, Columbus, Ohio, USA
William Drobyński, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
James Ferrara, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Sergio A. Giralt, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Theresa Hahn, Roswell Park Cancer Institute, Buffalo, New York, USA
Gregory A. Hale, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
Peiman Hematti, University of Wisconsin at Madison, Madison, Wisconsin, USA
Vincent Ho, Dana-Farber Cancer Institute, Boston, Maryland, USA
Mary Horowitz, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Mitchell Horowitz, Duke University School of Medicine, Durham, North Carolina, USA
Bryon D. Johnson, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Richard J. Jones, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Matt Kalaycio, Cleveland Clinic Main Campus, Cleveland, Ohio, USA
Armando Kerh, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Hans-Jochem Kolb, Technische Universität München, München, Germany
Issa F. Khouz, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Hans-Jochem Kolb, Technische Universität München, München, Germany
John Koreth, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Hillel Lazarus, UH Case Medical Center, Cleveland, Ohio, USA
Helen Leather, University of Florida, Gainesville, Florida, USA
Catherine Lee, The University of Utah, Salt Lake City, Utah, USA
Stephanie J. Lee, University of Washington, Seattle, Washington, USA
Robert Levy, University of Miami, Miller School of Medicine, Miami, Florida, USA
Hao Liu, Baylor College of Medicine, Houston, Texas, USA
Brent Logan, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Leo Luznik, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
Navneet Majhail, Cleveland Clinic, Cleveland, Ohio, USA
David Marks, University Hospitals Bristol NHS Foundation Trust, Bristol, England, UK
Paul Martin, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
Jayesh Mehta, Northwestern Memorial Hospital, Chicago, Illinois, USA
Arnon Nagler, Chaim Sheba Medical Center, Tel Hashomer, Israel
Shinichiro Okamoto, Keio University School of Medicine, Tokyo, Japan
Steven Pavletic, National Institutes of Health (NIH), Bethesda, Maryland, USA
Luis F. Porrata, Mayo Clinic, Rochester, Minnesota, USA
Michael Pulsipher, University of Utah School of Medicine, Salt Lake City, Utah, USA
Vijay Reddy, Florida Hospital, Orlando, Florida, USA
Marcie Riches, UNC School of Medicine - Chapel Hill, Chapel Hill, North Carolina, USA
Olle Ringden, Karolinska Institutet, Stockholm, Sweden
Jerome Ritz, Dana-Farber Cancer Institute, Boston, Maryland, USA
Scott Rowley, Hackensack University Medical Center, Hackensack, New Jersey, USA
Kirk Schultz, University of British Columbia, Vancouver, British Columbia, Canada
Bronwen Shaw, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
Thomas Shea, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
Andre Tichelli, Universitätsspital Basel, Basel, Switzerland
Koen van Besien, Weill Cornell Medical College, Chicago, Illinois, USA
David Vesole, Hackensack University Medical Center
Georgia B. Vogelsang, Johns Hopkins University, Baltimore, Maryland, USA
Donna Wall, The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
Edmund Waller, Emory University, Atlanta, Georgia, USA
GUIDE FOR AUTHORS

Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

To find out more, please visit the Preparation section below.

Categories of manuscripts

Brief Articles. Reserved for cutting edge early studies that would highly impact the field. Manuscripts in this category are in the same format as a Regular Article, but are generally less than 20 total manuscript pages in length (double-spaced) and have three or less figures or tables.

Regular Manuscripts. Manuscripts submitted in this category are expected to be concise, well organized, and clearly written. Acceptance is based on originality and importance to the field of blood and marrow transplantation. These manuscripts are reviewed by two or more experts in the field, and detailed comments from the reviewers are generally returned to the authors. Manuscripts requiring extensive revision will be at a disadvantage for publication. Manuscripts are submitted with the understanding that they are original contributions and do not contain data that have been published elsewhere, including symposia volumes, etc. Meeting abstracts do not constitute prior publication.

Rapid Communications. Definitive papers of exceptional scientific importance within the discipline of blood and marrow transplantation will be considered for expedited review and publication. Consideration as a Rapid Communication must be requested at the time of submission by the authors and requires approval by the Editorial Board. Papers that the Editors decide not to process as Rapid Communications will be handled as regular manuscripts unless the authors choose to have them returned without further review. Criteria for selection as Rapid Communications include originality, importance, and the potential value of accelerated publication to the readers of Biology of Blood and Marrow Transplantation. Decisions on these manuscripts will be made within four weeks of receipt and in general will not be accompanied by detailed reviewers’ comments. Although there is no page limit for manuscripts in this category, clear and concise presentation of data is required. Manuscripts requiring extensive revisions or editing will be at a disadvantage for publication in this category. Case reports, methods papers, or preliminary studies should not be submitted for consideration as Rapid Communications.

Review Articles. Review articles on topics of broad interest are highly desired and may be solicited by the Editor-in-Chief. Individuals who wish to write a review article should correspond with the Editor in Chief regarding the appropriateness of the proposed topic. Such articles are expected to be thorough and detailed and should include appropriate references to the literature. The addition of tables and figures to summarize critical points is encouraged. These articles are reviewed by the Editors and other expert reviewers before a final decision regarding publication is made, and revisions may be required. Review articles should be limited to no more than 5,000 words (exclusive of references) and no more than 80 references.

Clinical Reviews. Short, highly focused articles that review topics related to therapy, diagnosis, or other clinical issues in hematology may be published as Clinical Reviews. Authors who wish to write a Clinical Review should correspond with the Editor in Chief regarding the proposed topic. Such manuscripts will be reviewed by expert reviewers and will be accepted for publication based on their educational value and clarity. Manuscript submission fees and page charges are not assessed on review articles.

Editorials. Concise, invited commentaries on articles published in Biology of Blood and Marrow Transplantation or other topics in hematology are highly desired.

Letters. Letters to the Editor commenting on articles published in Biology of Blood and Marrow Transplantation are welcomed. Letters should be as concise as possible (no more than three double-spaced pages), include no more than 10 references, and should have titles.

Case Reports are not published in BBMT, and will not be accepted in any format.
**Submission checklist**

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

**Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:
- E-mail address
- Full postal address

All necessary files have been uploaded:
- **Manuscript:**
  - Include keywords
  - All figures (include relevant captions)
  - All tables (including titles, description, footnotes)
  - Ensure all figure and table citations in the text match the files provided
  - Indicate clearly if color should be used for any figures in print

- **Graphical Abstracts / Highlights files** (where applicable)
- **Supplemental files** (where applicable)

**Further considerations**
- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](http://www.elsevier.com/locate/bbmt).

**BEFORE YOU BEGIN**

**Ethics in publishing**

Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

**Ethical Considerations.**

*Biology of Blood and Marrow Transplantation* considers research and publication misconduct to be a serious breach of ethics, and will take such actions as necessary to address such misconduct. Authors should refer to the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors for full information. Authors are also encouraged to visit Elsevier's Ethical Guidelines for Journal Publication.

Plagiarism and duplicate submission are serious acts of misconduct. Plagiarism is defined as unreferenced use of published or unauthorized use of unpublished ideas, and may occur at any stage of planning, researching, writing, or publication. Plagiarism takes many forms, from 'passing off' another's paper as the author's own paper, to copying or paraphrasing substantial parts of another's paper (without attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable. Duplicate submission/publication occurs when two or more papers, without full cross-reference, share the same hypothesis, data, discussion points, or conclusions.

**Declaration of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted.
2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

**Submission declaration and verification**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

**Preprints**
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

**Article transfer service**
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.

**Copyright**
All material in Biology of Blood and Marrow Transplantation represents the opinions of the authors and does not reflect the opinions of the American Society for Blood and Marrow Transplantation (ASBMT), Elsevier Inc., or the institutions with which the authors are affiliated. Authors submitting manuscripts do so with the understanding that, if accepted, copyright in the article, including the right to reproduce the article in all forms and media including electronic media, shall be assigned exclusively to the ASBMT and authors will be requested to sign a copyright release form.

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.
**NIH Public Access Policy Compliance**

To comply with the NIH Public Access Policy, Elsevier will deposit to PubMed Central (PMC) author manuscripts on behalf of authors reporting NIH funded research. The NIH policy requires that NIH-funded authors submit to PubMed Central (PMC), or have submitted on their behalf, their peer-reviewed author manuscripts, to appear on PMC no later than 12 months after final publication. Elsevier will send to PMC the final peer-reviewed manuscript, which was accepted for publication and sent to Elsevier's production department, and that reflects any author-agreed changes made in response to peer-review comments. Elsevier will authorize the author manuscript's public access posting 12 months after final publication. Following the deposit by Elsevier, authors will receive further communications from the NIH with respect to the submission.

Note: Authors must declare their NIH funding (or the other funding bodies listed below) when completing the copyright transfer form.

**Other Funding Body Policies**

Elsevier has also worked with the following funding bodies to ensure that our authors can comply with their policies:

- Arthritis Research Campaign (UK)
- British Heart Foundation (UK)
- Cancer Research (UK)
- Chief Scientist Office
- Department of Health (UK)
- Howard Hughes Medical Institute (US)
- Medical Research Council (UK)
- Wellcome Trust (UK)

For full details on how these policies are implemented, please see complete information at: [https://www.elsevier.com/fundingbodyagreements](https://www.elsevier.com/fundingbodyagreements)

**Funding body agreements and policies**

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of existing agreements are available online.

After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

**Open access**

This journal offers authors a choice in publishing their research:

**Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
- No open access publication fee payable by authors.
- The Author is entitled to post the accepted manuscript in their institution’s repository and make this public after an embargo period (known as green Open Access). The published journal article cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications. The embargo period for this journal can be found below.

**Gold open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.
Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

*Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 3650**, excluding taxes. There is a **10%** discount off the open access publication fee for members of the **American Society for Blood and Marrow Transplantation**. Learn more about Elsevier’s pricing policy: [https://www.elsevier.com/openaccesspricing](https://www.elsevier.com/openaccesspricing).

**Green open access**

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [open access page](https://www.elsevier.com/openaccess) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.

This journal has an embargo period of 12 months.

**Manuscript Submission and Handling**

Biology of Blood and Marrow Transplantation utilizes a web-based manuscript submission and peer-review system. Authors should submit their manuscripts, with figures and tables, electronically at the journal Web site, www.bbmt.org. Authors can also visit External link [http://ees.elsevier.com/ybbmt](http://ees.elsevier.com/ybbmt). Complete instructions are available at the Web site. If authors experience any difficulty during the submission process or require any assistance, they should visit External link [http://support.elsevier.com](http://support.elsevier.com). If authors do not receive an e-mail confirmation of submission within 24 hours, it may be an indication that the manuscript has not been received by the editorial office. In this instance, authors should contact the editorial office (Robert Korngold, PhD, Hackensack University Medical Center, 40 Prospect Avenue – Rm 356 Jurist Research Building, Hackensack, NJ 07601; Tel: (551) 996-8664; Fax: (551) 996-8696; Email:(Robert.Korngold@hackensackmeridian.org).

**Submit your article**

Please submit your article via [http://support.elsevier.com](http://support.elsevier.com).

**NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

**References**

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.
**Formatting requirements**

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

**Figures and tables embedded in text**

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

**REVISED SUBMISSIONS**

**Use of word processing software**

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Organization of the Manuscript**

Organize submitted manuscripts as follows: Cover Letter, Title Page (including title; authors' full names, academic degrees, and affiliations; corresponding author's address, phone number, fax number, and e-mail address; and a short title), Financial Disclosure Statement, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References, Tables, Figure Legends, and Figures. Manuscripts should be double-spaced and formatted for standard paper with 1-inch margins.

**Cover Letter.** Please identify the name, address, phone number, fax number, and e-mail address of the corresponding author. The cover letter should also specify the category of manuscript (such as Rapid Communication). Papers that the Editors decide not to process as Rapid Communications will be handled as regular manuscripts unless the authors request in the cover letter that the manuscript be returned without further review. The cover letter also should indicate where appropriate that the authors are willing to pay the extra costs involved in publishing any color photographs. At the end of the cover letter, all authors must sign a statement that they have reviewed the manuscript, agree with its contents, and consent to its submission to BBMT. The author agreement can alternatively be e-mailed as a pdf separately to the Editorial Office: Robert Korngold, Ph.D; E-mail: RKorngold@HackensackUMC.org.

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site.

Authors can make use of Elsevier's Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

**Highlights**

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site.
**Abbreviations**
Abbreviations should be defined at their first use and applied consistently throughout the article. Do not use nonstandard abbreviations or abbreviate terms appearing fewer than three times. Give the chemical name of a compound after the first use of the trivial name. The trivial name may follow throughout the article.

**Financial Disclosure Statement**
Authors must disclose any primary financial relationship with a company that has a direct financial interest in the subject matter or products discussed in the submitted manuscript, or with a company that produces a competing product. These relationships (such as honoraria, ownership of stock, patents, or consulting fees) and any direct support of research by a commercial company will be included in the Acknowledgements section of the published article.

**Footnotes**
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

**Electronic artwork**

**General points**
- Make sure you use uniform lettering and sizing of your original artwork.
- Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Indicate per figure if it is a single, 1.5 or 2-column fitting image.
- For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
- Please note that individual figure files larger than 10 MB must be provided in separate source files.

You are urged to visit this site; some excerpts from the detailed information are given here.

**Formats**
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

**EPS (or PDF)**: Vector drawings. Embed the font or save the text as 'graphics'.
**TIFF (or JPG)**: Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
**TIFF (or JPG)**: Bittedmaped line drawings: use a minimum of 1000 dpi.
**TIFF (or JPG)**: Combinations bittedmated line/half-tone (color or grayscale): a minimum of 500 dpi is required.

Please do not:
- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

Part of the cost of publishing color photographs will be borne by the authors and payment must be made to the publisher prior to publication. The cost to publish color figures in print is $500 for the first color figure and $100 for each additional color figure.

**Figures and Figure Legends**
Figures must be cited in the text in numerical order using Arabic numerals. Figures should be generated in .tif format; see instructions on Web site. Figure legends should be double-spaced on a separate page and should include a brief title and a concise explanation of each figure.

**Figure captions**
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

**Tables**
Each table should be printed or typed on a separate page, appropriately numbered and cited in numerical order in the text. Legends giving sufficient explanation to make the data intelligible without reference to the text must be typed on the same page.
References
Include double-spaced references in numerical order at the end of the article according to the order of citation in the text. The names of all authors should be given unless there are more than 6, in which case the names of the first 3 authors should be given, followed by "et al." Abbreviate the names of journals according to the abbreviations used in the latest edition of Index Medicus, Superintendent of Documents, US Government Printing Office, Washington, DC 20402. References to abstracts and letters must be appropriately identified. References to personal communications, unpublished observations, and manuscripts submitted and "in preparation" must appear parenthetically in the text.

If you do wish to format the references yourself they should be arranged according to the following examples:


There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

**Supplementary Material for Online Publication**

In cases where essential information associated with an article is too extensive for print publication (e.g., data sets, additional figures, video files), this content can be included as online-only supplemental information. Supplementary material file(s) should be provided at the time of manuscript submission, and should be called out in the text (e.g., Table S2, Fig S1, Item S4). Titles and/or legends for each supplementary figure or item should be included as the final page of the manuscript document. Unless otherwise requested, supplementary material will generally be corrected for style, grammar, and format.

**Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Mendeley Data**

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

**Data statement**

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.
Proofs
Authors of accepted manuscripts will receive galley proofs as pdf files via e-mail directly from the publisher and are responsible for proofreading. Except for correcting typesetting errors, authors may be charged for extensive alterations. Corrections should be returned within 48 hours to avoid delay in publication.

Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier’s Webshop. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

Reprints
Reprints must be ordered and paid for in advance. An order form with the cost of reprints and instructions for payment will be sent directly from the publisher with page proofs. Reprint orders, payments, and inquiries should be directed to Elsevier.

Announcements
Announcements of meetings that are of interest to the readers of Biology of Blood and Marrow Transplantation should be sent to the Editor at least three months before the first day of the month of issue. Fees for announcements vary depending on their size and number of insertions; please call the Editorial Office for details.

Advertisements

Publisher Contact Information:
Angela Welch
Publisher
Elsevier
360 Park Avenue South, New York, NY 10010-1710
E-mail: a.welch@elsevier.com

© Copyright 2018 Elsevier | https://www.elsevier.com